Workflow
灵康药业(603669) - 2024 Q4 - 年度业绩预告
603669Lionco(603669)2025-01-24 08:25

Financial Performance - The company expects a net profit attributable to shareholders of approximately -120 million yuan for 2024, a year-on-year reduction in losses of about 20.79%[2] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is approximately -165 million yuan, a year-on-year reduction in losses of about 9.26%[2] - The anticipated operating revenue for 2024 is around 380 million yuan, representing a year-on-year growth of approximately 93.06%[2] - The decline in gross profit due to centralized procurement has led to an inability to cover current period expenses, resulting in the expected loss for 2024[2] - The financial impact of the net profit loss will be confirmed in the company's audited annual report for 2024[2] Cost Management - The company is implementing refined management practices to control costs and maximize capacity utilization, contributing to a reduction in losses year-on-year[2] Credit Rating - The credit rating agency has downgraded the company's credit rating to A- with a stable outlook, effective from the date of the report[1] - The downgrade of the credit rating for the company's convertible bonds to A- is also effective from the same date[1] - The company will continue to monitor and disclose any changes in its operational and financial status that may affect its credit rating and outlook[2] - The announcement serves as a third-party reference opinion on the company's credit status and is not a recommendation for any specific decision[4]